Vaughan Clift - Ampio Pharm Chief Regulatory Affairs Officer

AMPE Stock  USD 0.92  0.10  12.20%   

Executive

Dr. Vaughan Lennox Clift, M.D., serves as Chief Regulatory Affairs Officer of Ampio Pharmaceuticals, Inc. Dr. Clift was employed as Ampios Chief Regulatory Affairs Officer from March 2010 until July 2016 and was employed by Life Sciences from May 2009 until March 2010. From 2005 to 2009, Dr. Clift was the chief executive officer of Detectachem LLC, a Houston, Texasbased manufacturer of a handheld explosive and narcotics detection device. Dr. Clift was the Vice President of Operations for Isolagen from 2002 until 2005.
Age 54
Address 9800 Mount Pyramid Court, Englewood, CO, United States, 80112
Phone720 437 6500
Webhttps://ampiopharma.com

Ampio Pharm Management Efficiency

The company has return on total asset (ROA) of (0.6157) % which means that it has lost $0.6157 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1396) %, meaning that it created substantial loss on money invested by shareholders. Ampio Pharm's management efficiency ratios could be used to measure how well Ampio Pharm manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to -2.44. In addition to that, Return On Assets is expected to decline to -1.58. At present, Ampio Pharm's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 12.4 M, whereas Non Current Assets Total are forecasted to decline to about 283 K.
The company currently holds 274 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Ampio Pharm has a current ratio of 4.75, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Ampio Pharm until it has trouble settling it off, either with new capital or with free cash flow. So, Ampio Pharm's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Ampio Pharm sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Ampio to invest in growth at high rates of return. When we think about Ampio Pharm's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

David StiresOlympic Steel
N/A
Sean HeenanOlympic Steel
43
Eyal GoldsteinAsure Software
48
Kevin MillerOlympic Steel
N/A
Yasmine RodriguezAsure Software
N/A
Cassandra PowersOlympic Steel
N/A
Patrick McKillopAsure Software
N/A
Francis RuaneOlympic Steel
N/A
Michelle SPHROlympic Steel
N/A
Paul CPANextplat Corp
67
CPA PhillipNextplat Corp
65
Matthew DennisOlympic Steel
N/A
James PostOlympic Steel
N/A
Michele PeppersCECO Environmental Corp
42
Carolyn BassAsure Software
N/A
Matthew GrussingOlympic Steel
N/A
Mike VannoyAsure Software
N/A
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19 and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. Ampio Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 18 people. Ampio Pharm (AMPE) is traded on NYSE MKT Exchange in USA. It is located in 9800 Mount Pyramid Court, Englewood, CO, United States, 80112 and employs 18 people. Ampio Pharm is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Ampio Pharm Leadership Team

Elected by the shareholders, the Ampio Pharm's board of directors comprises two types of representatives: Ampio Pharm inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ampio. The board's role is to monitor Ampio Pharm's management team and ensure that shareholders' interests are well served. Ampio Pharm's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ampio Pharm's outside directors are responsible for providing unbiased perspectives on the board's policies.
CPA CPA, Corp CFO
Laura Goldberg, VP Operations
Daniel Stokely, CFO, Corporate Secretary
MBBCh MMM, Chief Officer
Holli Cherevka, COO
David Stevens, Independent Director
Daniel CPA, Corporate CFO
Lane Hapke, VP Operations
April Ramirez, Clinical Manager
Michael Martino, CEO Director
Michael MacAluso, Founder, Chairman and CEO
Thomas Chilcott, Interim CFO
Vaughan Clift, Chief Regulatory Affairs Officer
Philip Coelho, Director, Chairman of Compensation Committee, Chairman of Nominating and Governance Committee and Member of Audit Committee
Richard Giles, Director of Investor Relations, Director, Chairman of Audit Committee, Member of Nominating and Governance Committee and Member of Compensation Committee
Gregory Gould, CFO, Treasurer, Corporate Secretary
David BarOr, Chief Scientific Officer, Director
David MD, Founder Board

Ampio Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ampio Pharm a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Ampio Pharm in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Ampio Pharm's short interest history, or implied volatility extrapolated from Ampio Pharm options trading.

Pair Trading with Ampio Pharm

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ampio Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ampio Pharm will appreciate offsetting losses from the drop in the long position's value.

Moving together with Ampio Stock

  0.64MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr

Moving against Ampio Stock

  0.62MESO Mesoblast Upward RallyPairCorr
  0.51MDWD Mediwound Downward RallyPairCorr
The ability to find closely correlated positions to Ampio Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ampio Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ampio Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ampio Pharm to buy it.
The correlation of Ampio Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ampio Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ampio Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ampio Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Ampio Pharm is a strong investment it is important to analyze Ampio Pharm's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ampio Pharm's future performance. For an informed investment choice regarding Ampio Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ampio Pharm. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
For information on how to trade Ampio Stock refer to our How to Trade Ampio Stock guide.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Ampio Stock analysis

When running Ampio Pharm's price analysis, check to measure Ampio Pharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ampio Pharm is operating at the current time. Most of Ampio Pharm's value examination focuses on studying past and present price action to predict the probability of Ampio Pharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ampio Pharm's price. Additionally, you may evaluate how the addition of Ampio Pharm to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Is Ampio Pharm's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ampio Pharm. If investors know Ampio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ampio Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(11.70)
Return On Assets
(0.62)
Return On Equity
(1.14)
The market value of Ampio Pharm is measured differently than its book value, which is the value of Ampio that is recorded on the company's balance sheet. Investors also form their own opinion of Ampio Pharm's value that differs from its market value or its book value, called intrinsic value, which is Ampio Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ampio Pharm's market value can be influenced by many factors that don't directly affect Ampio Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ampio Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ampio Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ampio Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.